Search

Editas Medicine Inc

Cerrado

SectorSanidad

2.92 3.55

Resumen

Variación precio

24h

Actual

Mínimo

2.68

Máximo

2.88

Métricas clave

By Trading Economics

Ingresos

6.8M

-18M

Ventas

9.1M

12M

BPA

-0.15

Margen de beneficios

-153.322

Empleados

87

EBITDA

3.9M

-20M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+112.96% upside

Dividendos

By Acuity

Próximas Ganancias

9 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

14M

421M

Apertura anterior

-0.63

Cierre anterior

2.92

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

97 / 339 Clasificación en Healthcare

Editas Medicine Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 sept 2026, 21:51 UTC

Editas Medicine Inc is trading higher in after-market hours, recovering from significant volatility, but remains 2.00% below its 20-day moving average.

18 sept 2026, 21:51 UTC

Editas Medicine Inc is advancing in after-market trading, moving higher alongside the broader market amid macroeconomic concerns and geopolitical tensions.

17 sept 2026, 23:01 UTC

Editas Medicine Inc is higher in after-market trading, recovering from earlier lows, though it remains below its 20-day moving average.

16 sept 2026, 20:07 UTC

Editas Medicine Inc is gaining in Wednesday's session, reflecting a positive trend since Tuesday's close, despite remaining below its 20-day moving average.

15 sept 2026, 23:51 UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

10 sept 2026, 20:08 UTC

Correlated Moves

Editas Medicine Inc shares are lower, extending a three-day decline amid broader biotechnology sector weakness and pressures from the European Central Bank's recent interest rate hike.

9 sept 2026, 22:11 UTC

Editas Medicine Inc shares are higher in after-market trading, reflecting a notable increase since Wednesday's close, despite being below its 20-day moving average.

8 sept 2026, 20:08 UTC

News

Editas Medicine appoints Dan Ory as Chief Medical Officer, shares decline sharply amid market response. The stock has reached a session low today.

4 sept 2026, 23:02 UTC

Editas Medicine Inc shares are lower during after-market hours, reflecting a decline despite being above its 20-day moving average and near one-month highs.

1 sept 2026, 19:16 UTC

News

Editas Medicine is participating in two investor conferences, enhancing visibility. Shares are higher today, reflecting positive investor interest in its CRISPR technology focus.

31 ago 2026, 22:51 UTC

News

Editas Medicine has filed a prospectus for a $400 million mixed securities shelf offering, contributing to higher shares during after-market hours.

28 ago 2026, 20:03 UTC

Editas Medicine Inc shares are lower today, retracing from earlier highs. Broader market dynamics, including rising Treasury yields, may be contributing to the decline.

27 ago 2026, 23:02 UTC

Editas Medicine Inc is trading higher in after-market hours, reflecting positive sentiment since Thursday's close and resilience despite earlier session pullbacks.

26 ago 2026, 23:16 UTC

Editas Medicine Inc shares are higher in after-market trading, positioned near the upper end of their one-month range and above the 20-day moving average.

25 ago 2026, 19:21 UTC

Correlated Moves

Editas Medicine Inc is seeing gains during Tuesday's session, reaching a peak return earlier before pulling back slightly. Broader market sentiment remains favorable for biotech stocks.

24 ago 2026, 22:22 UTC

Editas Medicine Inc shares are higher in after-market trading, showing some volatility. No specific news was identified to explain the price movement.

21 ago 2026, 23:16 UTC

Editas Medicine Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock remains above its 20-day moving average.

20 ago 2026, 23:46 UTC

Editas Medicine Inc is higher in after-market hours, gaining since Thursday's close. The stock is above its 20-day moving average amid no specific news.

19 ago 2026, 23:21 UTC

Editas Medicine Inc. shares are lower in after-market hours, impacted by a decline in the Biotechnology sub-sector. No specific news was identified for the movement.

17 ago 2026, 19:16 UTC

Editas Medicine Inc. shares are trading roughly flat amid overall market sentiment influenced by recent declines in U.S. retail sales and consumer sentiment.

14 ago 2026, 22:21 UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

13 ago 2026, 21:32 UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

12 ago 2026, 19:31 UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

11 ago 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10 ago 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7 ago 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6 ago 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5 ago 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31 jul 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30 jul 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

Comparación entre iguales

Cambio de precio

Editas Medicine Inc previsión

Precio Objetivo

By TipRanks

112.96% repunte

Estimación a 12 Meses

Media 5.75 USD  112.96%

Máximo 8 USD

Mínimo 4 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

1

Mantener

1

Vender

Sentimiento

By Acuity

97 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.